GLP-1 weight loss drugs drive 20% drop in restaurant consumption

The rise of GLP-1 receptor agonists, medications originally designed for diabetes and now widely used for weight loss, is significantly impacting the restaurant industry. Dr. Richard Maríne, a specialist in nutrition and sports medicine, reports a 20% decrease in customer attendance and consumption in restaurants.

This shift is characterized by a sharp decline in alcohol sales and changes in eating habits. Families that previously dined out frequently are reducing their visits and requesting smaller portions. Dr. Maríne explains that these drugs act on the brain's reward centers, reducing the desire for food and alcohol. He notes that consuming fried foods, sweets, or alcohol while on these treatments can trigger adverse health reactions, including vomiting, diarrhea, and migraines.